ERB-196

ERB-196
Clinical data
Other names	WAY-202196
Identifiers
	IUPAC name 3-(3-Fluoro-4-hydroxyphenyl)-7-hydroxynaphthalene-1-carbonitrile;
CAS Number	550997-55-2;
PubChem CID	6102691;
DrugBank	DB06875;
ChemSpider	4810213;
UNII	470CL5L4AC;
ChEMBL	ChEMBL192154;
CompTox Dashboard (EPA)	DTXSID70422018 ;
Chemical and physical data
Formula	C17H10FNO2
Molar mass	279.270 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1(=CC2=C(C(=C1)C#N)C=C(C=C2)O)C1=CC(=C(C=C1)O)F;
	InChI InChI=1S/C17H10FNO2/c18-16-7-10(2-4-17(16)21)12-5-11-1-3-14(20)8-15(11)13(6-12)9-19/h1-8,20-21H; Key:NSSOSHDCWCMNDM-UHFFFAOYSA-N;

ERB-196, also known as WAY-202196, is a synthetic nonsteroidal estrogen that acts as a highly selective agonist of the ERβ.^[1]^[2]^[3]^[4]^[5]^[6] It possesses 78-fold selectivity for the ERβ over the ERα.^[1] The drug was under development by Wyeth for the treatment of inflammation and sepsis starting in 2004 but development was discontinued by 2011.^[2]^[7]